<code id='772BB98B2A'></code><style id='772BB98B2A'></style>
    • <acronym id='772BB98B2A'></acronym>
      <center id='772BB98B2A'><center id='772BB98B2A'><tfoot id='772BB98B2A'></tfoot></center><abbr id='772BB98B2A'><dir id='772BB98B2A'><tfoot id='772BB98B2A'></tfoot><noframes id='772BB98B2A'>

    • <optgroup id='772BB98B2A'><strike id='772BB98B2A'><sup id='772BB98B2A'></sup></strike><code id='772BB98B2A'></code></optgroup>
        1. <b id='772BB98B2A'><label id='772BB98B2A'><select id='772BB98B2A'><dt id='772BB98B2A'><span id='772BB98B2A'></span></dt></select></label></b><u id='772BB98B2A'></u>
          <i id='772BB98B2A'><strike id='772BB98B2A'><tt id='772BB98B2A'><pre id='772BB98B2A'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:focus    Page View:6
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In